Skip to main content
YUHAN CORPORATION logo

YUHAN CORPORATION — Investor Relations & Filings

Ticker · 000100 ISIN · KR7000100008 KO Manufacturing
Open in API
Filings indexed 633 across all filing types
Latest filing 2026-06-01 Director's Dealing
Country KR South Korea
Listing KO 000100

About YUHAN CORPORATION

http://eng.yuhan.co.kr

Yuhan Corporation, established in 1926, is an integrated healthcare company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. Its diverse portfolio encompasses prescription drugs, over-the-counter (OTC) medications, Active Pharmaceutical Ingredients (APIs), and intermediates for various therapeutic areas, including antibiotics and antivirals. The company also produces veterinary drugs and household goods. In addition to its own product lines, Yuhan operates as a Contract Development and Manufacturing Organization (CDMO), offering comprehensive services to the pharmaceutical sector. Through its affiliates, the company is also involved in specialized areas such as nutrient infusion solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is in Korean and is titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” which literally translates to a report of executive and major shareholder ownership of specific securities. It details an officer’s shareholding and changes (acquisitions/disposals) on specific dates, including share quantities and ownership ratios. This corresponds exactly to an insider trading or director dealing report. Under the taxonomy, this is classified as Director’s Dealing (Code: DIRS).
2026-06-01 Korean
기업지배구조보고서공시
Governance Information Classification · 92% confidence The document is titled “기업지배구조보고서 신고서” (Corporate Governance Report) and contains extensive details on governance policies, board composition, shareholder meeting practices, internal controls, CEO succession planning, and compliance with corporate governance key indicators. It is not merely an announcement of a report but the actual governance report itself. This matches the Governance Information category (CGR).
2026-06-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean “임원ㆍ주요주주 특정증권등 소유상황보고서” which translates to an officer and major shareholder report on specific securities ownership. It details an executive’s share purchases, holdings, percentages and transaction dates. This is a mandatory insider share transaction report by a company executive. It therefore falls under Director’s Dealing (insider trades) rather than a general shareholding notification or other report type.
2026-05-27 Korean
기업설명회(IR)개최(안내공시)
Regulatory Filings Classification · 82% confidence The document is a short regulatory announcement (안내공시) regarding the scheduling and format of an upcoming Investor Relations meeting (“기업설명회(IR) 개최”). It does not contain actual financial statements or presentation content, nor is it the publication of a report; it simply notifies the market of an event. Therefore it falls into the miscellaneous regulatory filings category (RNS).
2026-05-20 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 75% confidence The document is a corporate disclosure announcing the signing of a single sales and supply contract (API supply agreement) with Gilead Sciences. It provides contract details (amount, term, counterparty, payment terms) but does not include financial statements, earnings data, management changes, or governance materials. It is not an earnings release, interim report, annual report, board change, M&A notice, or other specific category. Therefore it falls under the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is the Korean ‘분기보고서’ (quarterly report) for the 1st quarter of the 104th fiscal period (2026-01-01 to 2026-03-31). It includes a full table of contents covering company overview, business activities, detailed financial statements, MD&A (경영진단 및 분석의견), audit opinion, and other comprehensive financial data. This matches the definition of an Interim/Quarterly Report rather than a simple announcement or certification. Q1 2026
2026-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.